Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Human Longevity Inc.

Human Longevity Inc.

Human genome sequencing company founded in 2013 and based in San Diego, CA. Human Longevity Inc. is building a database with genomic and phenotypic information and aims to make medicine more data-driven by combining DNA sequencing, expert analysis and machine learning

Human Longevity Inc. is a biotechnology company using biological data to create medicine that is headquartered in San Diego, California and was founded in 2013 by Craig Venter, Peter Diamandis, and Robert Hariri.

Human Longevity is developing a database on human genotypes and phenotypes to develop diagnostics and therapeutics against aging-related human diseases and conditions. Human Longevity Inc. databases are available to pharmaceutical, biotechnology and academic organizations.

They are developing cell-based therapeutics to address decline in endogenous stem cell function and also focus on cancer, diabetes, obesity, heart and liver diseases and dementia. The company performs sequencing and provides human genome sequencing and offers genomic analysis with predictive and preventative care, as well as cancer analysis, newborn screening and screening for rare and undiagnosed diseases. Human Longevity also provides personalized vaccines and cell therapies.

One of the co-founders of Human Longevity is J. Craig Venter which played a large role in the Human Genome Project. Venter left the company in May 2018 and has been accused of misappropriation of trade secrets in a Human Longevity lawsuit filed against him. Venter emailed a statement to Quartz stating that the claims are without merit and that the J. Craig Venter Institute will defend against the allegations and also that Venter is still a shareholder at Human Longevity Inc.

Funding
Series A

On March 4, 2014 Human Longevity completed their series A funding round with $80 million in funding from Synthetic Genomics, OS Fund, Illumina Ventures, DFJ, Celgene, Tan Thay, and Daniel Curran.

Series B

On April 5, 2016 Human Longevity completed their series B funding round with $220 million in funding from Illimina Ventures (lead investor), OS Fund, StartUp Health, GE Ventures, DFJ, Celgene, and Amino Capital.

Timeline

November 7, 2019
Human Longevity Inc. raises a $30,000,000 series C round from Emerging Technology Partners.
March 4, 2014
Human Longevity Inc. raises a $80,000,000 series A round from Celgene, Daniel Curran, Illumina, OS Fund, Synthetic Genomics and Threshold Ventures.
July 15, 2013
Human Longevity Inc. was founded by J. Venter, Peter Diamandis and Robert Hariri.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

Dr. Julie Chen at Chicago Fox 32 News on Breast Cancer Awareness

Web

October 19, 2021

Former unicorn genetics startup Human Longevity loses its horn

Kevin Truong

Web

December 10, 2018

Getting a Better Night's Sleep | KABC 5am Interview with Dr. Julie Chen from Human Longevity

Web

July 13, 2021

Guided Meditation | Loving Kindness Meditation

Web

March 7, 2021

Introducing Human Longevity, Inc. Health Nucleus

October 27, 2015

References

Golden logo
By using this site, you agree to our Terms & Conditions.